IMBdx is a precision oncology company committed to advancing safe and accurate cancer diagnosis, monitoring, and screening. We have developed a minimally-invasive liquid biopsy technology that detects cancer and monitors its progression with just a single blood draw.
Our AlphaLiquid® test provides comprehensive genomic profiling (CGP) of tumors, identifying key mutations and offering personalized treatment options, including matching therapies and relevant clinical trial opportunities.
In addition to AlphaLiquid®, we offer CancerDetectTM, a minimal residual disease (MRD) test that detects trace amounts of cancer cells remaining after treatment, allowing for early relapse detection. We also provide CancerFindTM, a multi-cancer early detection (MCED) test that screens for multiple types of cancer at once, even in asymptomatic patients, enabling earlier and more effective intervention.
Since beginning our research in 2014, our goal has been to make cancer diagnosis more accessible and affordable for patients worldwide.
For more information, please visit www.imbdx.com/eng/ or contact us at support@imbdx.com.
Company Details
- Employees
- 30
- Founded
- -
- Address
- Geumcheon-Gu, Seoul,korea, Republic Of
- Phone
- +82-2-6951-2906
- su****@****bdx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- imbdx.com
- Keywords
- IT Consulting.
- HQ
- Seoul
Imbdx Questions
Imbdx's helpline number is +82-2-6951-2906
Imbdx's website is imbdx.com
Imbdx's LinkedIn profile is https://kr.linkedin.com/company/imbdx
Imbdx has
30 employees.
View email and phone details for 30
employees at Imbdx.
Imbdx's industry is
Biotechnology Research
Imbdx's top competitors are
Macrogen Inc.,
Accolades Integrated,
Basgenbio (바스젠바이오),
Kipinn - Simplified Property Management,
Ezdiatech Inc.,
3billion,
Roche,
Xpertgen Inc. / 엑스퍼젠 주식회사,
Celemics, Inc.,
Zybisys.
Imbdx's support email address is support@imbdx.com
Imbdx's categories are Biotechnology Research
Imbdx's founding year is 2018
